AU2003246574A1 - Thiazine and oxazine derivatives as mmp-13 inhibitors for treating arthritis - Google Patents

Thiazine and oxazine derivatives as mmp-13 inhibitors for treating arthritis

Info

Publication number
AU2003246574A1
AU2003246574A1 AU2003246574A AU2003246574A AU2003246574A1 AU 2003246574 A1 AU2003246574 A1 AU 2003246574A1 AU 2003246574 A AU2003246574 A AU 2003246574A AU 2003246574 A AU2003246574 A AU 2003246574A AU 2003246574 A1 AU2003246574 A1 AU 2003246574A1
Authority
AU
Australia
Prior art keywords
thiazine
mmp
inhibitors
treating arthritis
oxazine derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003246574A
Inventor
Bernard Gaudilliere
Henry Jacobelli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Publication of AU2003246574A1 publication Critical patent/AU2003246574A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/24—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in positions 2 and 4
    • C07D265/26—Two oxygen atoms, e.g. isatoic anhydride
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/04—1,3-Thiazines; Hydrogenated 1,3-thiazines
    • C07D279/08—1,3-Thiazines; Hydrogenated 1,3-thiazines condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AU2003246574A 2002-06-25 2003-06-24 Thiazine and oxazine derivatives as mmp-13 inhibitors for treating arthritis Abandoned AU2003246574A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2002/008062 WO2004000321A1 (en) 2002-06-25 2002-06-25 Thiazine and oxazine derivatives as mmp-13 inhibitors for treating arthritis
EPPCT/EP/02/08062 2002-06-25
PCT/EP2003/006601 WO2004000322A1 (en) 2002-06-25 2003-06-24 Thiazine and oxazine derivatives as mmp-13 inhibitors for treating arthritis

Publications (1)

Publication Number Publication Date
AU2003246574A1 true AU2003246574A1 (en) 2004-01-06

Family

ID=29797117

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2002333256A Abandoned AU2002333256A1 (en) 2002-06-25 2002-06-25 Thiazine and oxazine derivatives as mmp-13 inhibitors for treating arthritis
AU2003246574A Abandoned AU2003246574A1 (en) 2002-06-25 2003-06-24 Thiazine and oxazine derivatives as mmp-13 inhibitors for treating arthritis

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AU2002333256A Abandoned AU2002333256A1 (en) 2002-06-25 2002-06-25 Thiazine and oxazine derivatives as mmp-13 inhibitors for treating arthritis

Country Status (6)

Country Link
JP (1) JP2005538965A (en)
AU (2) AU2002333256A1 (en)
BR (1) BR0312107A (en)
CA (1) CA2491210A1 (en)
MX (1) MXPA05000004A (en)
WO (2) WO2004000321A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8539501A1 (en) 2001-02-14 2002-09-30 Warner Lambert Co TRIAZOLO COMPOUNDS AS MMP INHIBITORS
US6962922B2 (en) 2001-10-12 2005-11-08 Warner-Lambert Company Llc Alkynylated quinazoline compounds
US6894057B2 (en) 2002-03-08 2005-05-17 Warner-Lambert Company Oxo-azabicyclic compounds
AU2003253186A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors
JP2006501215A (en) 2002-08-13 2006-01-12 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー Monocyclic derivatives as matrix metalloproteinase inhibitors
WO2004014375A2 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Fused bicyclic metalloproteinase inhibitors
PA8578101A1 (en) 2002-08-13 2004-05-07 Warner Lambert Co HETEROBIARILO DERIVATIVES AS METALOPROTEINASE IN MATRIX INHIBITORS
AU2003250470A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Pyrimidinone fused bicyclic metalloproteinase inhibitors
BR0313724A (en) 2002-08-13 2005-06-28 Warner Lambert Co Azaisoquinoline derivatives as matrix metalloproteinase inhibitors
AU2003253150A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Chromone derivatives as matrix metalloproteinase inhibitors
AU2003250471A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors
CN112159347B (en) * 2020-10-27 2022-06-07 常州工程职业技术学院 Preparation method of picolitamide

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6037454B2 (en) * 1976-12-17 1985-08-26 富士写真フイルム株式会社 Heat-developable photosensitive material

Also Published As

Publication number Publication date
MXPA05000004A (en) 2005-04-08
JP2005538965A (en) 2005-12-22
CA2491210A1 (en) 2003-12-31
BR0312107A (en) 2005-03-29
WO2004000322A1 (en) 2003-12-31
AU2002333256A1 (en) 2004-01-06
WO2004000321A1 (en) 2003-12-31

Similar Documents

Publication Publication Date Title
AU2003293356A1 (en) Dihydropyridinone derivatives as hne inhibitors
AU2003258045A1 (en) Novel gamma-lactams as beta-secretase inhibitors
AU2003298540A1 (en) Process and apparatus for microreplication
AU2002213336A1 (en) Substituted heterocyclic compounds for treating multidrug resistance
AU2003226168A1 (en) Fluorochemical treatment for silicon articles
AU2003217159A1 (en) Compositions and methods for the treatment of wastewater and other waste
AU2003268241A1 (en) Procedure for jammer detection
AU2003212894A1 (en) Compositions and methods for treating diarrhea
AU2003246574A1 (en) Thiazine and oxazine derivatives as mmp-13 inhibitors for treating arthritis
AU2003203170A1 (en) Nitrogenous heterocyclic compounds, process for preparation of the same and use thereof
AU2002225930A1 (en) Methods for treating phosphatide-containing mixtures
AU2003261738A1 (en) Gloves and method of knitting the same
AU2003230392A1 (en) Beta-secretase inhibitors
AU2003249181A1 (en) Methods for treating or preventing ischemic injury
AU2001275085A1 (en) Methods, compounds and compositions for treating gout
AU2003241599A1 (en) Compositions and methods for the treatment of hemophilia a
AU2003251766A1 (en) Partially ester-exchanged sipm and process therewith
AU2003292231A1 (en) Methods for diagnosing and treating schizophrenia
AU2003222058A1 (en) Materials and methods for inhibiting wip-1
AU2003259202A1 (en) Compositions and methods for treating and preventing infection
AU2003273904A1 (en) Method and arrangement for the thermal treatment of a workpiece
AU2003277598A1 (en) Treating agent for masonry
AU2003242755A1 (en) Novel pharmaceutical compositions comprising novel anticholinergic agents and pde-iv inhibitors
AU1039801A (en) Compounds and their use as cysteine protease inhibitors
AU2003205452A1 (en) Bmp inhibitors for the treatment of spondyloarthropathies

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase